Pharming up 22% after resuming trading following announcement of FDA approval

Shares of Pharming are up $2.45, or 22%, to $13.73 after the company announced that the Food and Drug Administration has approved Joenja for the treatment of activated phosphoinositide 3-kinase delta syndrome, or APDS, in adult and pediatric patients 12 years of age and older.